CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124
|
作者：
Maisey, NR [1 ]
Norman, AR [1 ]
Hill, A [1 ]
Massey, A [1 ]
Oates, J [1 ]
Cunningham, D [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期
关键词：
pancreatic cancer; CA19-9; prognosis; chemotherapy;
D O I：
10.1038/sj.bjc.6602760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).
引用
收藏
页码：740 / 743
页数：4
相关论文
共 50 条
  • [1] CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
    N R Maisey
    A R Norman
    A Hill
    A Massey
    J Oates
    D Cunningham
    British Journal of Cancer, 2005, 93 : 740 - 743
  • [2] Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer
    Asaoka, Tadafumi
    Miyamoto, Atsushi
    Maeda, Sakae
    Tsujie, Masanori
    Hama, Naoki
    Yamamoto, Kazuyoshi
    Miyake, Masakazu
    Haraguchi, Naotsugu
    Nishikawa, Kazuhiro
    Hirao, Motohiro
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Nakamori, Shoji
    PANCREATOLOGY, 2016, 16 (03) : 434 - 440
  • [3] CA19-9 AND PANCREATIC-CANCER
    DUNN, PM
    MCKINSTRY, M
    ANNALS OF INTERNAL MEDICINE, 1989, 111 (04) : 343 - 343
  • [4] CA19-9 is an independent prognostic factor for locally advanced pancreatic cancer patients treated with chemoradiotherapy
    Chung, M. J.
    Hong, S. P.
    Bang, S. M.
    Park, S. W.
    Seoung, J. S.
    Lee, W. J.
    Chung, J. B.
    Song, S. Y.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A129 - A129
  • [5] Prognostic Value of CA19-9 Level for Locally Advanced Pancreatic Cancer
    Abreu, A.
    Ho, A. Y.
    Huguet, F.
    Kuk, D.
    Zhang, Z.
    O'Reilly, E. M.
    Goodman, K. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S333 - S333
  • [6] CA19-9 as a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
    Luo, G.
    Guo, M.
    Liu, Z.
    Liu, C.
    Cheng, H.
    Lu, Y.
    Jin, K.
    Zhang, B.
    Liu, L.
    Long, J.
    Xu, J.
    Ni, Q.
    Chen, J.
    Yu, X.
    NEUROENDOCRINOLOGY, 2016, 103 : 49 - 49
  • [7] CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer
    Mie, Takafumi
    Ozaka, Masato
    Okamoto, Takeshi
    Takeda, Tsuyoshi
    Ushida, Yuta
    Mori, Chinatsu
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Sasaki, Takashi
    Inoue, Yousuke
    Takahashi, Yu
    Sasahira, Naoki
    IN VIVO, 2022, 36 (06): : 2844 - 2851
  • [8] CA19-9 for detecting recurrence of pancreatic cancer
    Azizian, Azadeh
    Ruehlmann, Felix
    Krause, Tanja
    Bernhardt, Markus
    Jo, Peter
    Koenig, Alexander
    Kleiss, Mathias
    Leha, Andreas
    Ghadimi, Michael
    Gaedcke, Jochen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [9] CA19-9 and CEA biosensors in pancreatic cancer
    Ahmadipour, Mohsen
    Bhattacharya, Anish
    Sarafbidabad, Mohsen
    Sazali, Ezza Syuhada
    Ghoshal, Sib Krishna
    Satgunam, Meenaloshini
    Singh, Ramesh
    Ardani, Mohammad Rezaei
    Missaoui, Nadhem
    Kahri, Hamza
    Pal, Ujjwal
    Pang, Ai Ling
    CLINICA CHIMICA ACTA, 2024, 554
  • [10] Ca19-9 and pancreatic cancer: Is it really that good?
    Morris-Stiff, Gareth
    Taylor, Mark A.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (02) : 88 - 89
12345